GlassScriptPhysician profile
Carl J Erickson
NPI 1093027518
$3,428.40
in general payments reported to CMS, 2019-2025
20 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $128 · 2021: $115 · 2022: $282 · 2023: $206 · 2024: $1,080 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,494 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,493.77 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,113.76 | 2022-2025 | Precision 1, Dailies Total1, Precision7 |
| Coopervision INC. | $512.85 | 2019-2025 | Myday Contact Lens |
| Biotissue Holdings INC. | $411.22 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $285.01 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $283.56 | 2022-2025 | Infuse, Xiidra, Miebo |
| Abbvie INC. | $191.56 | 2022-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $148.21 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $109.58 | 2021-2023 | |
| Dompe US, INC. | $71.21 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $70.39 | 2019-2024 | |
| Rxsight INC | $49.43 | 2024 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Allergan, INC. | $30.14 | 2021-2022 | |
| Shire North American Group INC | $25.88 | 2019 | |
| Astellas Pharma US INC | $23.23 | 2023 | |
| Optos, INC. | $22.58 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $20.58 | 2022 | |
| Lombart Brothers, INC. | $19.47 | 2019 | |
| Aerie Pharmaceuticals, INC. | $16.28 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $12.12 | 2019 | |
| Sight Sciences, INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.